Cytokinetics sues Bristol Myers, MyoKardia seeking ruling on MYQORZO patent dispute

• Cytokinetics filed a complaint on Aug. 13, 2026 in U.S. District Court in Delaware against Bristol-Myers Squibb, MyoKardia.
• Suit seeks a declaratory judgment of non-infringement of U.S. Patent No. 12,616,697, covering MYQORZO (aficamten).
• Company also asks the court to invalidate the patent claims, citing uncertainty over the outcome of litigation.
• Filing requests injunction to stop defendants from threatening or bringing patent suits tied to MYQORZO.
• Cytokinetics demanded a jury trial, seeking costs and attorneys’ fees under 35 U.S.C. § 285.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-348060), on August 13, 2026, and is solely responsible for the information contained therein.